產(chǎn)品詳情
簡(jiǎn)單介紹：
Anti-SLC44A4抗體產(chǎn)品質(zhì)量穩(wěn)定，實(shí)驗(yàn)效果明顯，貨期快，價(jià)格優(yōu)惠，歡迎垂詢訂購(gòu)！我公司長(zhǎng)期供應(yīng)**組化抗體、WB抗體、**組化試劑盒和抗體試驗(yàn)所需全部相關(guān)試劑、熒光標(biāo)記抗體、單克隆抗體、多克隆抗體、各種標(biāo)記的二抗IgG/IgM/IgD/IgA等科研實(shí)驗(yàn)抗體。Anti-SLC44A4抗體用于**組化實(shí)驗(yàn),WB實(shí)驗(yàn),相應(yīng)的標(biāo)記抗體有HRP標(biāo)記抗體,FITC標(biāo)記,BIO等。
詳情介紹：
Rabbit Anti-SLC44A4
Cat. Number:
Anti-SLC44A4抗體KL-13961R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
Choline is an essential nutrient that is required for the synthesis of both acetylcholine, a neurotransmitter found in cholinergic nerve terminals, and phosphatidylcholine, a key component of cell membranes. CholineAnti-SLC44A4抗體 deficiencies are associated with defects in cell growth and have been implicated in disorders such as Alzheimer’s and Parkinson’s disease. The choline transporter-like protein family (CTL) are solute carriers that transport choline, a compound which is not able to permeate cells, across the cell membrane. CTL4, also known as SLC44A4 (Solute carrier family 44 member 4), is a multi-pass membrane protein which can fuse with Neu1, generating a CTL4-Neu1 transcript. This fusion is implicated in sialidosis, a disease characterized by improper lysosomal storage.
Also known as:
Solute carrier family 44, member 4; Anti-SLC44A4抗體SLC44A4; CTL4; FLJ14491; NG22; CTL4_HUMAN.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, Horse, .
●
Immunogen: KLH conjugated Anti-SLC44A4抗體synthetic peptide derived from human SLC44A4.
●
Predicted Molecular Weight: 79kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 Anti-SLC44A4抗體
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
